{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-24-000168","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.472268+00:00","generated_at":"2026-05-30T05:56:45.576098+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M","bullets":["Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.","Total test reports 26,010 (+41% YoY); TissueCypher up 115%, IDgenetix up 81%, DecisionDx-SCC up 49%.","Raises full-year 2024 revenue guidance to $320-330M from prior $275-300M.","Cash, equivalents and marketable securities $279.8M at Sept 30, 2024.","Q3 operating cash flow $23.3M vs $5.0M prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-24-000168","json":"https://secwatch.observer/filing/0001447362-24-000168.json","markdown":"https://secwatch.observer/filing/0001447362-24-000168.md","text":"https://secwatch.observer/filing/0001447362-24-000168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000168/0001447362-24-000168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000168/cstl-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:56:45.576098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}